June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
In vivo imaging of a new indocyanine green micelle formulation in an animal model
Author Affiliations & Notes
  • Steffen Schmitz-Valckenberg
    Ophthalmology, University of Bonn, Bonn, Germany
  • Johanna Meyer
    Ophthalmology, University of Bonn, Bonn, Germany
  • Alexander Cunea
    Ophthalmology, University of Bonn, Bonn, Germany
  • Pia Welker
    mivenion GmbH, Berlin, Germany
  • Kai Licha
    mivenion GmbH, Berlin, Germany
  • Dagmar Sonntag-Bensch
    Ophthalmology, University of Bonn, Bonn, Germany
  • Frank Holz
    Ophthalmology, University of Bonn, Bonn, Germany
  • Footnotes
    Commercial Relationships Steffen Schmitz-Valckenberg, Heidelberg Engineering (F), Optos (F), Carl Zeiss Meditec (F), Heidelberg Engineering (R), Genentech (C), Novartis (C), Novartis (R), Roche (R), Novartis (F); Johanna Meyer, Heidelberg Engineering (F), Carl-Zeiss Meditec AG (F); Alexander Cunea, Carl Zeiss Meditec (F), Heidelberg Engineering (F); Pia Welker, mivenion (E); Kai Licha, mivenion GmbH (E); Dagmar Sonntag-Bensch, Heidelberg Engineering (F), Carl-Zeiss Meditec AG (F); Frank Holz, Acucela (C), Allergan (C), Genentech (F), Heidelberg Engineering (F), Zeiss (F), Novartis (F), Novartis (C), Optos (F), Merz (C), Bayer (F), Bayer (C), Boehringer Ingelheim (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4887. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Steffen Schmitz-Valckenberg, Johanna Meyer, Alexander Cunea, Pia Welker, Kai Licha, Dagmar Sonntag-Bensch, Frank Holz; In vivo imaging of a new indocyanine green micelle formulation in an animal model. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4887.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate a novel optimized formulation of indocyanine green (ICG/Solutol HS15) in an animal model.

Methods: ICG was formulated with the nonionic solubilizer and emulsifying agent Solutol HS15 to create ICG/Solutol HS15 in order to improve the chemical stability and fluorescence efficacy. Using confocal scanning laser ophthalmoscopy (cSLO), in vivo reflectance and fluorescence (excitation 790 nm, emission > 820 nm) imaging were performed in Dark Agouti rats that had undergone argon laser photocoagulation to induce choroidal neovascularisations (CNV). Retinal uptake and fluorescence intensity of both conventional ICG and ICG/Solutol HS15 were compared following intravenous injection of 3 dosages: 0.05; 0.1 and 0.15 mg/kg body weight (b.w.). In vivo imaging was performed at three different time points: day 7, 14 and 21 days following laser treatment.

Results: In vivo imaging before dye application showed ill-defined retinal lesions at day 7. Immediately following intravenous dye injection, a strong fluorescence was visible in the retinal vasculature and at the site of laser lesions. Pixel intensity in the retinal vasculature (for all 3 dosages: day 7: p=0.01; day 14: p=0.01; day 21: p=0.01) and in the background was significantly higher for ICG/Solutol HS15 compared to conventional ICG at 8 minutes after injection for all time points. Also, pixel intensity in the laser lesion at 8 min was higher for 0,1 and 0,15 mg/kg b.w. ICG/Solutol HS15 compared to conventional ICG at day 7 (p=0.01) and day 21 (p=0.02). Over time, a continuous decrease of the fluorescent signal was observed for up to 60 minutes. No fluorescent signal of either ICG/Solutol HS15 or ICG was detectable one day after application.

Conclusions: The results demonstrate that micelle formulated ICG can be visualized in the retinal vasculature and laser-induced CNV showing overall stronger signal intensity as compared to conventional ICG for all tested dosages. Its spatio-temporal kinetics can be studied using in vivo cSLO imaging. Upon further investigations in animal models, ICG/Solutol HS15 may be applicable in patients with retinal and choroidal diseases for earlier and more refined diagnosis

Keywords: 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • 688 retina • 578 laser  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×